Bicycle Therapeutics plc Interest Expense
Bicycle Therapeutics plc (BCYC) reported Interest Expense of $821.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-02.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-05-02
- Bicycle Therapeutics plc interest expense for the quarter ending 2024-03-31 was $821.00K, a 1.61% increase year-over-year.
- Bicycle Therapeutics plc interest expense for the quarter ending 2023-12-31 was $820.00K, a 0.73% decline year-over-year.
- Bicycle Therapeutics plc interest expense for the quarter ending 2023-09-30 was $814.00K, a 0.37% decline year-over-year.
- Bicycle Therapeutics plc interest expense for the quarter ending 2023-06-30 was $821.00K, a 7.02% decline year-over-year.
- Bicycle Therapeutics plc interest expense for fiscal 2023 was $3.26M, a 2.42% decline from fiscal 2022.
- Bicycle Therapeutics plc interest expense for fiscal 2022 was $3.34M, a 12.06% increase from fiscal 2021.
- Bicycle Therapeutics plc interest expense for fiscal 2021 was $2.98M, a 552.95% increase from fiscal 2020.
- Bicycle Therapeutics plc interest expense for fiscal 2020 was $457.00K.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $821.00K 10-Q · filed 2024-05-02 | $1.64M derived: sum of 2 quarters · filed 2024-05-02 | $2.46M derived: sum of 3 quarters · filed 2024-05-02 | $3.28M derived: sum of 4 quarters · filed 2024-05-02 |
| 2023-12-31 | $820.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $1.63M derived: sum of 2 quarters · filed 2024-02-20 | $2.46M derived: sum of 3 quarters · filed 2024-02-20 | $3.26M 10-K · filed 2024-02-20 |
| 2023-09-30 | $814.00K 10-Q · filed 2023-11-02 | $1.64M derived: sum of 2 quarters · filed 2023-11-02 | $2.44M 10-Q · filed 2023-11-02 | $3.27M derived: sum of 4 quarters · filed 2024-05-02 |
| 2023-06-30 | $821.00K 10-Q · filed 2023-08-03 | $1.63M 10-Q · filed 2023-08-03 | $2.46M derived: sum of 3 quarters · filed 2024-05-02 | $3.27M derived: sum of 4 quarters · filed 2024-05-02 |
| 2023-03-31 | $808.00K 10-Q · filed 2024-05-02 | $1.63M derived: sum of 2 quarters · filed 2024-05-02 | $2.45M derived: sum of 3 quarters · filed 2024-05-02 | $3.33M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $826.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $1.64M derived: sum of 2 quarters · filed 2024-02-20 | $2.53M derived: sum of 3 quarters · filed 2024-02-20 | $3.34M 10-K · filed 2024-02-20 |
| 2022-09-30 | $817.00K 10-Q · filed 2023-11-02 | $1.70M derived: sum of 2 quarters · filed 2023-11-02 | $2.52M 10-Q · filed 2023-11-02 | $3.34M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $883.00K 10-Q · filed 2023-08-03 | $1.70M 10-Q · filed 2023-08-03 | $2.52M derived: sum of 3 quarters · filed 2024-02-20 | $3.34M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $818.00K 10-Q · filed 2023-05-04 | $1.64M derived: sum of 2 quarters · filed 2024-02-20 | $2.46M derived: sum of 3 quarters · filed 2024-02-20 | $3.28M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $820.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $1.64M derived: sum of 2 quarters · filed 2024-02-20 | $2.46M derived: sum of 3 quarters · filed 2024-02-20 | $2.98M 10-K · filed 2024-02-20 |
| 2021-09-30 | $823.00K 10-Q · filed 2022-11-03 | $1.64M derived: sum of 2 quarters · filed 2022-11-03 | $2.16M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $819.00K 10-Q · filed 2022-08-04 | $1.34M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $522.00K 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $457.00K 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |